Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The role of bendamustine in the treatment of mantle cell lymphomas

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.02.11
Views: 8931

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line treatment for MCL, Prof Rummel outlines his latest results presented at ASH 2010. These results establish the superiority of bendamustine plus rituximab over fludarabine plus rituximab in patients with relapsed MCL in terms of both efficacy and toxicity profile.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation